Super Micro Employees Detained in Taiwan AI Server Export Investigation 
Oil Prices Slip as Iran Talks and Strong Supply Outlook Ease Market Concerns 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
Gold Price Holds Above $4,000 as Fed Rate Hike Expectations and U.S. Jobs Data Weigh on Market 
US Resumes Dollar Shipments to Iraq After Months-Long Suspension 
SoftBank’s LY Corp, Bain Raise Kakaku.com Bid to ¥670 Billion, Intensifying Takeover Battle 
Japan Signals Readiness to Act on Yen as Intervention Speculation Grows 
Denmark Central Bank Intervenes to Support Krone Peg Against Euro 
Moody’s Says Peru’s President-Elect Keiko Fujimori Could Boost Investor Confidence 
Asian Stocks Slide as Chip Shares Tumble Ahead of Key U.S. Jobs Report 
Turkey Vehicle Sales Fall 11.4% in June as Auto Market Weakens 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
US Dollar Rises as Fed Rate Outlook Stays Hawkish, Euro Slips and Yen Near 40-Year Low 
Sodexo Raises 2026 Revenue Outlook After Strong Q3 Sales Beat 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Samsung Biologics is expanding its CMO or contract manufacturing organization business, and as part of its plans, it is constructing its very first overseas production plant in the United States.
On Monday, June 13, Samsung Biologics’ chief executive officer, John Rim, shared that they are considering several locations for the facility. He said that the strongest candidates for their CMO site are Texas, North Carolina, California, and Washington.
According to The Korea Herald, Samsung Biologics is looking into these places more because many of the major bio companies’ facilities are also operating in the mentioned US states. At this time, the company has not yet made any decision and carefully reviewing the areas to choose the best option.
“We are certainly expanding and the Plant 4 will begin partial operation in October, adding a 60,000-liter production capacity,” the Samsung Biologics’ CEO told the media during the press meeting for the 2022 BIO International Convention in San Diego, California. “By the second quarter of next year, it will have a 180,000-liter production capacity.”
While planning to build its first manufacturing plant abroad, Samsung Biologics has already set up its fourth factory in Songdo, Incheon, in South Korea. Once this facility starts operating at its full capacity, it is expected to boost production.
All in all, the four plants should produce 620,000 liters of products for around 30% of the global demand. It was said that Samsung Biologics’ Plant 4 currently has the biggest CMO production capacity in the world, with 256,000 liters of products in a single facility.
Rim revealed that they are also aiming to build the fifth and sixth factories in South Korea, and this is why they are buying more land in Incheon. The purchases were originally expected to be completed by the end of May, but the authorities could not sign the contract because the government officials who are in charge, which are the mayor and commissioner of the Incheon Free Economic Zone, have changed due to the local elections that was held earlier this month.
Finally, the Samsung Biologics chief said that they still plan to go ahead with the construction of Plant 5 and 6. However, they will not be monitoring the supply and demand trends to see if there is still a need to build more factories.
